Dr. Dawn Bell has been starting and scaling life-science businesses from academic spinouts to Top 5 Pharma for over 20 years. She is a founder, operator, and board director with diverse experience across drug development and commercialization. Her career spans buy and sell-side BD&L, portfolio strategy, R&D, medical affairs, and market access in both private and public companies (NYSE: NVS; NASDAQ: MDCO). She is CEO of Antlia Biosciences, a pre-clinical stage company developing long-acting peptides for patients with severe cardiovascular diseases, where she raised a $12M seed backed by Curie Bio and F-Prime. She is also co-founder and board director of Myracle Therapeutics, an academic spinout targeting adipocytes in obesity and metabolic health. She serves on the board of New York BIO.Career HighlightsDelivered Entresto ($6B) approval 18 months ahead of schedule as global GM. Led 100+ person team responsible for global strategy, regulatory approval, and reimbursement. Secured Break-Through and Fast-Track status at the FDA.Led development and launch of 12+ medicines across 8 therapeutic areas. Built the team that launched the 1st two gene therapies approved in Canada.Serial founder of two academic spin outs from University of Colorado and Emory University. Led sell-side BD&L process resulting in out-licensing of a novel biologic for rare hematologic disorders; Buy-side BD&L experience at Novartis leading white space portfolio strategy with full visibility into BD&L and M&A decision-making and governance processes.Early commercial leader at The Medicines Company (NASDAQ: MDCO) contributing to market cap growth from $400M to >$2B over 3 years.